Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SEER 
Seer Inc (SEER)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: SEER (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.17% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 108.17M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 3 | Beta 1.59 | 52 Weeks Range 1.62 - 2.59 | Updated Date 12/1/2025 |
52 Weeks Range 1.62 - 2.59 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.36 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.31 | Actual -0.32 |
Profitability
Profit Margin - | Operating Margin (TTM) -469.45% |
Management Effectiveness
Return on Assets (TTM) -15.19% | Return on Equity (TTM) -25.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -67873340 | Price to Sales(TTM) 6.61 |
Enterprise Value -67873340 | Price to Sales(TTM) 6.61 | ||
Enterprise Value to Revenue 0.11 | Enterprise Value to EBITDA 1.72 | Shares Outstanding 51761273 | Shares Floating 39347724 |
Shares Outstanding 51761273 | Shares Floating 39347724 | ||
Percent Insiders 3.35 | Percent Institutions 63.32 |
Upturn AI SWOT
Seer Inc
Company Overview
History and Background
Seer, Inc. was founded in 2017 and is a life sciences company focused on enabling proteomic research and improving healthcare outcomes. It went public in 2020.
Core Business Areas
- Proteomics Platform: Seer develops and commercializes a proteomics platform based on its proprietary engineered nanoparticles (NPs) technology. This platform enables researchers to deeply, unbiasedly, and rapidly analyze proteomes to improve disease understanding and treatment.
Leadership and Structure
Omead Ostadan is the CEO of Seer, Inc. The company has a typical structure for a publicly traded biotech, with departments spanning research, development, sales, marketing, and operations. They have a board of directors that oversees the company's strategic direction.
Top Products and Market Share
Key Offerings
- Proteograph Product Suite: The Proteograph Product Suite is Seer's core offering, which includes engineered nanoparticles, consumables, and instruments used for proteomics research. Market share is still developing, but Seer is aiming to disrupt the traditional proteomics market. Competitors include traditional proteomics platforms like mass spectrometry from companies like Thermo Fisher Scientific (TMO) and newer proteomics technologies from companies like SomaLogic.
Market Dynamics
Industry Overview
The proteomics market is growing rapidly, driven by increasing demand for personalized medicine and biomarker discovery. The market is competitive, with both established players and innovative startups.
Positioning
Seer is positioned as an innovator in proteomics, offering a platform that enables deeper and more unbiased proteomic analysis. This positions it to compete with traditional methods and capture a significant share of the expanding market.
Total Addressable Market (TAM)
The proteomics market is estimated to be worth billions of dollars. Some projections estimate the TAM at over $20 Billion. Seer aims to capture a significant portion of this TAM by enabling more comprehensive and efficient proteomic analysis.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Potential to disrupt the proteomics market
- Strong intellectual property position
- Experienced management team
Weaknesses
- Relatively young company
- Limited commercial track record
- High reliance on a single product platform
- Cash burn
Opportunities
- Expanding proteomics market
- Partnerships with pharmaceutical companies and research institutions
- Adoption of platform in clinical diagnostics
- Expanding to new applications
Threats
- Competition from established players
- Technological advancements by competitors
- Regulatory hurdles
- Economic downturns impacting research budgets
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- SomaLogic (SLGC)
- Bruker Corporation (BRKR)
Competitive Landscape
Seeru2019s competitive advantage lies in its novel nanoparticle technology, offering potentially deeper proteomic insights. However, it faces strong competition from established players with broader product portfolios and significant resources. SomaLogic has a well established market share with their SomaScan platform.
Major Acquisitions
n/a
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: n/a
Growth Trajectory and Initiatives
Historical Growth: Historical growth data requires access to prior years' financial statements.
Future Projections: Future projections depend on analyst estimates and company guidance, which are not readily available.
Recent Initiatives: Recent initiatives would need to be gathered from SEER's press releases and investor presentations.
Summary
Seer Inc. is an innovative proteomics company with a potentially disruptive technology. It faces competition from established players and needs to scale its commercial operations. While its technology offers advantages, financial sustainability and market adoption are key challenges. Successfully executing partnerships and expanding into clinical applications will be vital for future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
The data provided is based on publicly available information and analyst estimates. Actual results may vary. This is not financial advice; consult with a qualified professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Seer Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2020-12-04 | Founder, CEO, & Chair of the Board of Directors Dr. Omid C. Farokhzad M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 134 | Website https://seer.bio |
Full time employees 134 | Website https://seer.bio | ||
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.